A Controlled Intervention Study with Antibiotics in Symptomatic Coronary Patients Irrespective of Serology

  • E. Gurfinkel


Since the first coronary artery bypass surgery in 1967, 30 years have passed with few medical strategies proven effective in the treatment of acute coronary syndromes [1, 2]. In spite of it and many new antithrombotic compounds, a sizable proportion of patients are still developing new ischemic episodes, which may indicate that we have reached a biological barrier where any attempt to increase efficacy leads to the loss of security.


Acute Coronary Syndrome Human Leukocyte Antigen Coronary Artery Bypass Surgery Macrolide Antibiotic Clin Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gurfinkel E, on behalf of the principal contributors (1998) Current treatment and future prospects for the management of acute coronary syndromes. Consensus Recommendation of the 1997 Ushuaia Conference, Tierra del Fuego, Argentina. Clin Drug Invest 15: 368–380CrossRefGoogle Scholar
  2. 2.
    Gurfinkel E, Fareed J, Antman E, Cohen M, Mautner B (1998) The rationale for the management of acute coronary syndromes with low molecular weight heparins. Am J Cardiol 82: 15L–18LPubMedCrossRefGoogle Scholar
  3. 3.
    Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B for the Roxis Study Group (1997) Randomised trial of roxithromycin in non-Q-wave coronary syndromes: Roxis pilot study. Lancet 350: 404–407PubMedCrossRefGoogle Scholar
  4. 4.
    Gurfinkel E, Bozovich G, Livellara G, Beck E, Testa E, Mautner B (1999) Antibiotics for the treatment of non-Q-wave coronary syndromes. The Final Report of the ROXIS Trial. Eur Heart J 15: 368–380Google Scholar
  5. 5.
    Grayston JT, Kuo C-C, Coulson AS et al (1995) Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 92: 3397–3400PubMedGoogle Scholar
  6. 6.
    Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS (1998) Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 19: 387–394PubMedCrossRefGoogle Scholar
  7. 7.
    Bozovich G, Gurfinkel E, Raimondi E, Padrós K, Mejaíl I, Haas E et al (1997) Major histocompatibility complex and the vulnerable plaque in acute coronary syndromes. Potential modulation of the inflammatory response. Puerto Rico Health Sciences Journal 16: 5Google Scholar
  8. 8.
    Kadota JL (1996) Non-antibiotic effects of antibiotics. J Clin Microb Infect [Suppl II]: 220-222Google Scholar

Copyright information

© Springer-Verlag Italia, Milano 1999

Authors and Affiliations

  • E. Gurfinkel

There are no affiliations available

Personalised recommendations